We are pleased to announce our participation in the upcoming Spanish Drug Discovery Network (SDDN) 2025 meeting, taking place in A Coruña.

Representing the company will be our CEO, Enrique Sánchez, and our lead researcher responsible for the biological validation of BFlow, Andrea Balsa. They will engage with peers and experts from across the Spanish drug discovery ecosystem. The SDDN annual meeting brings together researchers, companies, and innovation leaders from across Spain who are shaping the future of drug discovery and early-stage biomedical development.

As drug discovery continues to evolve, research teams increasingly demand tools that deliver physiological relevance, reproducibility, and automation in the earliest phases of development. BFlow addresses these needs by providing a user-friendly organ-on-chip system specifically designed to streamline workflows and reduce experimental variability.

Our involvement in SDDN reflects BFlow’s mission to enable more predictive and physiologically relevant in vitro models for early-stage research, supporting scientists in reducing variability and enhancing data quality, two key challenges in drug development pipelines. Throughout the event, our team will share insights on the latest developments at BFlow and explore new collaboration opportunities within the scientific and industrial community.

BFlow remains committed to empowering the next generation of drug discovery tools, and events like SDDN reinforce the importance of working together to shape the future of biomedical research.